Circadian Rhythm and Melatonin in the Treatment of Depression

Author(s): Senthil Kumaran Satyanarayanan, Huanxing Su, Yi-Wen Lin, Kuan-Pin Su*.

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 22 , 2018

Become EABM
Become Reviewer

Abstract:

Background: Circadian rhythm disruption underlies the pathophysiology of psychiatric disorders, especially depression. Both pharmacological and non-pharmacological strategies affecting endogenous circadian rhythms have been developed with specificity to alter the circadian dysfunction. The current management strategy with antidepressants is far from being satisfactory in addressing this issue. In recent years, attempts at discovering new antidepressants focused on a melatonergic system which is known to be altered in depression have led to a potential option for treatment of depression.

Methods: We reviewed all recently published relevant articles on melatonin and its analogues to look for their implication in the treatment of circadian rhythm disruption and depression.

Results: Melatonin, a pleiotropic regulator molecule and its analogues (ramelteon, agomelatine, TIK-301, Neu- P11 and tasimelteon) have been observed to resynchronize the circadian rhythm and some were said to alleviate depressive symptoms in depressed subjects.

Conclusion: This review focuses on substantial advances in the melatonin-based chronobiologic intervention and its responses in the treatment of depression.

Keywords: Circadian rhythm, depression, melatonin, melatonin receptor agonists, pharmacology, antidepressants.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 24
ISSUE: 22
Year: 2018
Page: [2549 - 2555]
Pages: 7
DOI: 10.2174/1381612824666180803112304
Price: $58

Article Metrics

PDF: 43
HTML: 6
EPUB: 2
PRC: 1